Patents by Inventor Maria A. Bednarek

Maria A. Bednarek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20220098265
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 31, 2022
    Inventors: BALAJI AGORAM, Madeleine Antonsson, MARIA A. BEDNAREK, Nicole Burmeister, Lambertus Benthem, DAVID FAIRMAN, MARIA FRITSCH-FREDIN, Ronald JACKSON, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 11230584
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 25, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGS
    Publication number: 20210221866
    Abstract: The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substitution of alpha-methyl functionalized amino acids for natural amino acids has been determined to produce protease-resistant peptides.
    Type: Application
    Filed: February 8, 2021
    Publication date: July 22, 2021
    Inventors: JEFFERSON REVELL, MARIA BEDNAREK
  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20200115431
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 16, 2020
    Inventors: Balaji AGORAM, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David FAIRMAN, Maria FRITSCH-FREDIN, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGS
    Publication number: 20200079833
    Abstract: The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substituition of alpha-methyl functionalized amino acids for natural amino acids has been determined to produce protease-resistant peptides.
    Type: Application
    Filed: July 25, 2019
    Publication date: March 12, 2020
    Inventors: Jefferson Revell, Maria Bednarek
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 10556939
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: February 11, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Protease-resistant lipidated GLP-1 analogs
    Patent number: 10414811
    Abstract: The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substitution of alpha-methyl functionalized amino acids for natural amino acids has been determined to produce protease-resistant peptides.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: September 17, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Jefferson Revell, Maria Bednarek
  • PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGS
    Publication number: 20180162920
    Abstract: The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substitution of alpha-methyl functionalized amino acids for natural amino acids has been determined to produce protease-resistant peptides.
    Type: Application
    Filed: June 9, 2016
    Publication date: June 14, 2018
    Inventors: Jefferson REVELL, Maria BEDNAREK
  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20170342121
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 9765130
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: September 19, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
    Patent number: 9714277
    Abstract: This disclosure provides pegylated GLP-1/glucagon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 25, 2017
    Assignee: MedImmune Limited
    Inventor: Maria Bednarek
  • PROTEASE RESISTANT PEPTIDES
    Publication number: 20160318987
    Abstract: The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. Incorporation of alpha-methyl-functionalized amino acids directly into the main chain during standard peptide synthesis via the methodologies described herein has been determined to produce protease-resistant peptides.
    Type: Application
    Filed: December 10, 2014
    Publication date: November 3, 2016
    Inventors: JEFFERSON D. REVELL, MARIA A. BEDNAREK
  • GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES
    Publication number: 20160185837
    Abstract: This disclosure provides GIP/GLP-1 dual agonist polypeptides for the treatment of hypoglycemic conditions, e.g., type-2 diabetes.
    Type: Application
    Filed: August 15, 2014
    Publication date: June 30, 2016
    Applicant: Medimmune Limited
    Inventors: Maria Bednarek, Andie Collinson, David Hornigold, Siobhan O'Brien, Monika Papworth, Peter Ravn, Isabelle Sermadiras
  • PEGYLATED GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20160017016
    Abstract: This disclosure provides pegylated GLP-1/glucagon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Applicant: MEDIMMUNE LIMITED
    Inventor: Maria Bednarek
  • Glucagon/GLP-1 Agonists For The Treatment Of Obesity
    Publication number: 20150307579
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 29, 2015
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • NEUROMEDIN U RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20100075907
    Abstract: Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed.
    Type: Application
    Filed: November 20, 2009
    Publication date: March 25, 2010
    Inventors: Donald J. Marsh, Antonello Pessi, Maria A. Bednarek, Elisabetta Bianchi, Paolo Ingallinella, Andrea M. Peier
  • Melanin-concentrating hormone antagonists
    Patent number: 7335723
    Abstract: The present invention features MCH antagonists active at the MCH-1R. The antagonists are optionally modified peptides able to inhibit the effect of MCH at MCH-1R. MCH antagonists have a variety of uses including being used as a research tool and being used to achieve a beneficial effect in a subject.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: February 26, 2008
    Assignee: Merck & Co., Inc.
    Inventor: Maria A. Bednarek
  • Melanin-concentrating hormone analogs
    Patent number: 7314861
    Abstract: The present invention features truncated MCH analogs active at the melanin concentrating hormone type 2 receptor (MCH-2R) and uses of such analogs. Truncated MCH analogs described herein include those active at MCH-2R and MCH-1R, and those selectively active at MCH-2R. MCH-2R analogs have a variety of different uses including being used as a research tool and being used therapeutically.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: January 1, 2008
    Assignee: Merck & Co., Inc.
    Inventor: Maria Bednarek
  • Neuromedin U receptor agonists and uses thereof
    Publication number: 20070244048
    Abstract: Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed.
    Type: Application
    Filed: March 16, 2007
    Publication date: October 18, 2007
    Inventors: Donald Marsh, Antonella Pessi, Maria Bednarek, Elisabetta Bianchi, Paolo Ingallinella, Andrea Peier
  • Selective melanin-concentrating hormone type-1 receptor agonists
    Patent number: 7273846
    Abstract: The present invention features truncated hMCH analogs selectively active at MCH-1R over MCH-2R. Using amino acid numbering provided in hMCH, the featured analogs contain an X6 which is either a D-amino acid, 5-guanidinopropionic acid or its lower or higher homolog, or a derivative thereof; and a X10 which is either asparagine, glutamine, alanine, leucine, isoleucine, valine, norleucine, cyclohexylalanine, phenylalanine, (2?)-naphthylalanine, tyrosine, histidine, tryptophan, lysine, serine, threonine, methionine, or a derivative thereof.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: September 25, 2007
    Assignee: Merck & Co., Inc.
    Inventor: Maria A. Bednarek